Aug 3, 2020
|
Ardelyx Selected as a Finalist in the Fierce Innovation Awards for the Development of its First-in-Class Product Candidate Tenapanor
|
Jun 30, 2020
|
Ardelyx Announces Submission of New Drug Application to the U.S. FDA for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
|
Jun 15, 2020
|
Ardelyx Announces Positive Second Data Analysis from Ongoing NORMALIZE Phase 4 Study Evaluating Tenapanor in CKD Patients on Dialysis
|
Jun 9, 2020
|
Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
Jun 8, 2020
|
Ardelyx Appoints Veteran Biopharma Executive, Justin Renz, as Chief Financial Officer
|
May 26, 2020
|
Ardelyx to Present at the Jefferies 2020 Virtual Healthcare Conference
|
May 21, 2020
|
Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
May 18, 2020
|
Ardelyx Strengthens Management Team with Appointment of Susan Rodriguez as Chief Commercial Officer
|
May 7, 2020
|
Ardelyx Reports First Quarter 2020 Financial Results and Recent Business Highlights
|
Mar 16, 2020
|
Ardelyx Appoints Onaiza Cadoret-Manier to its Board of Directors
|